Bure Equity AB/Skr BURE

1D1W1MYTD1Y5YMAX

About Bure Equity AB

Bure Equity AB is an investment company based in Stockholm, Sweden, focusing on long-term ownership of companies with strong growth potential. The firm engages in the acquisition, development, and management of a diverse portfolio, encompassing sectors like technology, healthcare, industrials, and financial services. Founded in 1992, Bure Equity operates by actively supporting the strategic efforts of its portfolio companies to enhance value and growth. With a strong presence primarily in the Nordic region, the company leverages its expertise in governance and industry knowledge to drive successful outcomes. Bure Equity's strategic approach emphasizes long-term value creation and active involvement in its investments.
Ticker
Skr BURE
Sector
Finance
Primary listing
XSTO
Employees
12
Headquarters
Stockholm, Sweden
Website
www.bure.se/en/home-en

Bure Equity AB Metrics

BasicAdvanced
kr 23B
4.55
kr 67.66
1.29
kr 2.75
0.89%

Bulls say / Bears say

NAV per share rose 28.4% in the first half to SEK342.9, versus 8.1% for SIX RX, more than recovering the 2025 decline. This shows the portfolio can rebound strongly when key holdings recover. (Bure Equity)
Mycronic’s shares rose 47% in the second quarter, all divisions improved order intake, and its board raised the full-year sales forecast; Yubico’s sales rose 12% with a much better operating margin. That gives Bure tangible operating momentum rather than relying only on valuation changes. (Bure Equity)
Bure’s Ovzon exit generated a SEK410m profit and a 15.4% IRR, while the Silex listing broadened funding and ownership. These exits suggest active ownership can crystallise gains and recycle capital. (Bure Equity, Bure Equity)
The recovery was concentrated: Mycronic, Yubico and Silex accounted for most of the second-quarter NAV gain, with Mycronic alone adding SEK4.6bn. Bure is therefore highly sensitive to a setback in a small number of holdings, particularly Mycronic. (Bure Equity)
The portfolio showed sharp downside when sentiment turned: NAV per share fell 9% in the first quarter, Yubico fell 54.4%, Vitrolife 31.2%, and Mentimeter was written down by SEK173m amid AI-related software valuation concerns. That highlights valuation and mark-to-market risk even when underlying businesses are improving. (Bure Equity)
Bure’s share delivered only 9.1% total return in the first half while NAV rose 28.4%, so investors did not receive most of the underlying rebound. The gap suggests the market can keep a discount on Bure, limiting returns even if portfolio values rise. (Bure Equity)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.

Funds containing Bure Equity AB

AllEURGBPUSD
Funds
Fund name
Fund size
Skr BURE weighting
Xtrackers MSCI Europe Small Cap€DX2J
€3.2B0.11%
Xtrackers MSCI Europe Small Cap£XXSC
£2.8B0.11%
Vanguard ESG Global All Cap€V3AA
€1.1B0.01%
iShares MSCI World Small Cap$WSML
$9B0.01%
iShares MSCI World Small Cap€IUSN
€7.8B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.